Roger Perlmutter (Eikon)
June 17, 2022 05:32 AM EDTUpdated 11:42 AM
Startups

New kid on the block: Roger Perl­mut­ter's biotech signs on as an­chor ten­ant to new Bay Area cam­pus

Amber Tong

Hav­ing left be­hind a stel­lar lega­cy in Mer­ck’s head­quar­ters in Ke­nil­worth, NJ, Roger Perl­mut­ter’s next chap­ter of drug R&D will be writ­ten in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times